Table 4. Relative risk of falls outcomes at follow-up by OH categories (OH40 and sustained OH) stratified by supine or seated hypertension.
| Recurrent falls RR (95%CI) |
Injurious falls RR (95%CI) |
Unexplained falls RR (95%CI) |
Syncope RR (95%CI) |
|
|---|---|---|---|---|
| OH40 | ||||
| HTN- (supine) | 1.26 [0.86,1.84] | 1.30 [0.90,1.89] | 1.72 [1.07,2.77]* | 1.09 [0.59,2.04] |
| HTN+ (supine) | 1.52 [1.10,2.09]* | 1.55 [1.14,2.10]** | 1.54 [1.00,2.39] | 0.91 [0.53,1.55] |
| Sustained OH | ||||
| HTN- (supine) | 1.39 [0.84,2.30] | 1.66 [1.08,2.55]* | 1.53 [0.74,3.18] | 0.92 [0.37,2.26] |
| HTN+ (supine) | 1.45 [0.90,2.34] | 1.49 [1.00,2.22]* | 2.05 [1.16,3.62]* | 0.91 [0.48,1.75] |
| OH40 | ||||
| HTN- (seated) | 1.04 [0.70,1.54] | 1.11 [0.78,1.58] | 1.31 [0.77,2.23] | 1.19 [0.71,2.01] |
| HTN+ (seated) | 1.59 [1.16,2.17]** | 1.87 [1.38,2.54]*** | 2.14 [1.42,3.24]*** | 0.81 [0.46,1.42] |
| Sustained OH | ||||
| HTN- (seated) | 1.09 [0.64,1.85] | 1.46 [0.94,2.27] | 1.27 [0.57,2.81] | 1.35 [0.70,2.58] |
| HTN+ (seated) | 1.52 [0.97,2.39] | 1.75 [1.19,2.58]** | 2.51 [1.50,4.21]*** | 0.79 [0.42,1.49] |
ACE, angiotensin-converting enzyme; HTN-, not classified as having hypertension; HTN+, classified as having hypertension; OH40, orthostatic hypotension at 40 seconds.
Adjusted for age, sex, education, living alone or with others, follow-up time, number of follow-up waves available, angina, heart attack, diabetes, stroke or TIA, heart murmur, irregular heart rhythm, cataracts, glaucoma, age-related macular degeneration, cancer, arthritis, MOCA, CES-D, postural dizziness, baseline systolic blood pressure and heart rate, gait speed, grip strength, BMI, alpha blockers, beta blockers, calcium channel blockers, diuretics, ACE inhibitors, antidepressants.
*p<0.05,
**p<0.01,
***p<0.001.